Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Share

IMAGE: Virginia Borges, M.D., MMSc, and colleagues report promising phase 1b results for tucatinib and T-DM1 against HER2+ breast cancer. view more 

Credit: University of Colorado Cancer Center

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.

“At University of Colorado Cancer Center, we’ve worked with this drug since it was discovered by ARRAY BioPharma in Boulder. First it was ARRAY-380, then ONT-380 and now it’s called tucatinib. Since then, our institution has taken a lead effort in bringing it into trials and now into places where we are seeing it provide real benefit for women,” says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women’s Breast Cancer Translational Program at CU Cancer Center.

About 20 percent of breast cancers are considered HER2-positive, meaning that these cancer cells overexpress “receptors” that bind human epidermal growth factor 2 (HER2). When HER2 receptors

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD